Table 1. Antiproliferative effect of **curcumin** after 48h of treatment on **HCT116** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 0 | 0 | 0±0 |
| 50 | 3 | 1 | 2±1 |
| 25 | 18 | 6 | 12±8 |
| 12.5 | 51 | 39 | 45±8 |
| 6.25 | 75 | 61 | 68±10 |
| 3.125 | 88 | 85 | 86±2 |
| 1.5625 | 87 | 84 | 85±2 |
| 0.78125 | 88 | 82 | 85±4 |
| 0.390625 | 83 | 83 | 83±0 |
| 0.195313 | 95 | 82 | 88±9 |
| IC50, µM | 14.3 | 11.1 | 12.7±2.3 |
| R2 | 0.994 | 0.993 | - |

Table 2. Antiproliferative effect of **compound 5** after 48h of treatment on **HCT116** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 2 | 0 | 1±1 |
| 50 | 4 | 5 | 4±1 |
| 25 | 5 | 2 | 3±2 |
| 12.5 | 18 | 15 | 16±2 |
| 6.25 | 30 | 27 | 28±5 |
| 3.125 | 52 | 45 | 48±4 |
| 1.5625 | 95 | 90 | 92±4 |
| 0.78125 | 99 | 95 | 97±3 |
| 0.390625 | 92 | 95 | 93±2 |
| 0.195313 | 93 | 96 | 94±2 |
| IC50, µM | 3.736 | 3.267 | 3.502±0.332 |
| R2 | 0.982 | 0.986 | - |

Table 3. Antiproliferative effect of **compound 6** after 48h of treatment on **HCT116** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 3 | 12 | 7±6 |
| 50 | 9 | 13 | 11±3 |
| 25 | 10 | 18 | 14±6 |
| 12.5 | 15 | 24 | 19±6 |
| 6.25 | 13 | 20 | 16±5 |
| 3.125 | 24 | 38 | 31±10 |
| 1.5625 | 35 | 50 | 42±11 |
| 0.78125 | 81 | 91 | 86±7 |
| 0.390625 | 79 | 89 | 84±7 |
| 0.195313 | 77 | 91 | 84±10 |
| IC50, µM | 1.439 | 2.443 | 1.941±0.710 |
| R2 | 0.985 | 0.994 | - |



Fig.1. Cell growth inhibitory effect of compounds 5, 6 and curcumin on HCT116 cell line. Average value from two independent experiment, R>0.950.

Table 4. Antiproliferative effect of **curcumin** after 48h of treatment on **MDA-MB-231** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 0 | 0 | 0±0 |
| 50 | 2 | 12 | 7±7 |
| 25 | 43 | 39 | 41±3 |
| 12.5 | 53 | 46 | 49±5 |
| 6.25 | 82 | 80 | 81±1 |
| 3.125 | 89 | 88 | 88±1 |
| 1.5625 | 99 | 92 | 95±5 |
| 0.78125 | 99 | 95 | 97±3 |
| 0.390625 | 96 | 95 | 95±1 |
| 0.195313 | 102 | 98 | 100±3 |
| IC50, µM | 19.7 | 18.2 | 18.9±1.1 |
| R2 | 0.982 | 0.987 | - |

Table 5. Antiproliferative effect of **compound 5** after 48h of treatment on **MDA-MB-231** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 12 | 14 | 13±1 |
| 50 | 18 | 25 | 21±5 |
| 25 | 25 | 36 | 30±8 |
| 12.5 | 67 | 78 | 72±8 |
| 6.25 | 76 | 80 | 78±3 |
| 3.125 | 80 | 85 | 82±4 |
| 1.5625 | 84 | 88 | 86±3 |
| 0.78125 | 85 | 90 | 87±4 |
| 0.390625 | 93 | 92 | 92±1 |
| 0.195313 | 95 | 94 | 94±1 |
| IC50, µM | 16.2 | 19.2 | 17.7±2.2 |
| R2 | 0.975 | 0.98 |  |

Table 6. Antiproliferative effect of **compound 6** after 48h of treatment on **MDA-MB-231** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 18 | 20 | 19±1 |
| 50 | 25 | 22 | 23±2 |
| 25 | 36 | 32 | 34±3 |
| 12.5 | 43 | 44 | 43±1 |
| 6.25 | 58 | 59 | 58±1 |
| 3.125 | 69 | 71 | 70±1 |
| 1.5625 | 91 | 95 | 93±3 |
| 0.78125 | 88 | 92 | 90±3 |
| 0.390625 | 87 | 92 | 89±4 |
| 0.195313 | 95 | 97 | 96±1 |
| IC50, µM | 7.536 | 6.834 | 7.185±0.496 |
| R2 | 0.983 | 0.988 | - |



Fig.2. Cell growth inhibitory effect of compounds 5, 6 and curcumin on MDA-MB-231 cell line. Average value from two independent experiment, R>0.950.

Table 7. Antiproliferative effect of **curcumin** after 48h of treatment on **GM08402** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 6 | 10 | 8±3 |
| 50 | 22 | 26 | 24±3 |
| 25 | 58 | 61 | 59±2 |
| 12.5 | 75 | 77 | 76±1 |
| 6.25 | 86 | 85 | 85±1 |
| 3.125 | 85 | 90 | 87±4 |
| 1.5625 | 89 | 89 | 89±0 |
| 0.78125 | 95 | 92 | 93±2 |
| 0.390625 | 95 | 92 | 93±2 |
| 0.195313 | 95 | 94 | 94±1 |
| IC50, µM | 69.7 | 81.3 | 75.5±8.2 |
| R2 | 0.985 | 0.986 | - |

Table 8. Antiproliferative effect of **compound 5** after 48h of treatment on **GM08402** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 2 | 2 | 2±0 |
| 50 | 27 | 22 | 24±4 |
| 25 | 50 | 51 | 50±1 |
| 12.5 | 58 | 57 | 57±1 |
| 6.25 | 78 | 79 | 78±1 |
| 3.125 | 92 | 90 | 91±1 |
| 1.5625 | 93 | 98 | 95±4 |
| IC50, µM | 35.3 | 31.1 | 33.2±3.0 |
| R2 | 0.985 | 0.986 | - |

Table 9. Antiproliferative effect of **compound 6** after 48h of treatment on **GM08402** cell line by MTT assay

|  |  |
| --- | --- |
| Conc., µM | Viability % ±SD |
| 1st exp. | 2nd exp. | Average |
| 100 | 38 | 32 | 35±4 |
| 50 | 59 | 62 | 60±2 |
| 25 | 81 | 76 | 78±4 |
| 12.5 | 91 | 95 | 93±3 |
| 6.25 | 95 | 95 | 95±0 |
| 3.125 | 94 | 92 | 93±1 |
| IC50, µM | 99.3 | 91.9 | 95.6±5.2 |
| R2 | 0.994 | 0.982 | - |



Fig.3. Cell growth inhibitory effect of compounds 5, 6 and curcumin on GM08402 cell line. Average value from two independent experiment, R>0.950.